For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patientsSingle ...
T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...
The approach relies on a specially engineered scaffold that links three naturally occurring cytokines known to promote immune memory.
MRD testing promises sharper DLBCL response tracking than PET scans, cutting false positives, biopsies, and guiding therapy ...
A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...
Immune system cells can be engineered outside of the body in a type of therapy called CAR-T. Now, Johns Hopkins scientists are developing ways to sidestep such cell manufacturing with a biodegradable ...
Interim phase 1b data showed 100% partial response rate in efficacy-evaluable CLL/SLL (4/4) after a median of at least three prior treatment lines. In heavily pretreated MZL (n=5), three complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results